Rapid Micro Biosystems AI Stock Analysis
Want to see RPID full AI Analyst Report?
Rapid Micro Biosystems (RPID) AI Stock Analysis
Rapid Micro Biosystems
(NASDAQ:RPID)
The score is held down primarily by weak financial performance—large ongoing losses, sustained cash burn, and rising leverage—despite improving gross margin and revenue growth. Technicals remain weak with the stock below key longer-term moving averages. Offsetting these risks are constructive earnings-call progress (reaffirmed/raised operational targets and improving margin outlook) and a highly supportive corporate event: a signed all-cash acquisition agreement at $0.75 per share.
Rapid Micro Biosystems (RPID) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $33.64M
- Dividend Yield
- ―
- Average Volume (3M)
- 540.87K
- Price to Earnings (P/E)
- -0.7
- Beta (1Y)
- 1.39
- Revenue Growth
- 20.78%
- EPS Growth
- -9.39%
- Country
- US
- Employees
- 171
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Rapid Micro Biosystems Business Overview & Revenue Model
Company Description
Rapid Micro Biosystems, Inc. operates as a life sciences technology firm, supplying advanced solutions for identifying microbial impurities in the production processes of pharmaceuticals, medical devices, and personal care goods across North America,...
How the Company Makes Money
Rapid Micro Biosystems makes money primarily by selling its Growth Direct systems and then generating recurring revenue from the installed base through consumables and services. Key revenue streams include: (1) Instrument/system sales: one-time reven...
Rapid Micro Biosystems Earnings Call Summary
The call conveyed clear operational momentum: double-digit revenue growth (11% YoY), record consumable performance (>20% growth), a company milestone (200th system), a sizable increase in service margins (to 49%), and a pathway to improving gross margins through H2 2026 and longer-term targets (50% by end of 2028). At the same time, the company remains unprofitable with a Q2 net loss of $12.9M and adjusted EBITDA loss of $10.3M, product margins are still slightly negative, and liquidity depends on achieving debt milestone funding and potential warrant exercises. Overall, management emphasized improving fundamentals and execution while acknowledging remaining execution and financing risks.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Rapid Micro reaffirmed full‑year 2026 guidance of $37–$41 million in revenue and 30–38 system placements, raised validation guidance to at least 27 completions (with ≥10 in Q3), and expects full‑year gross margin of ~20% (product margin mid‑to‑high single digits; service margin 45–50%). For Q3 they forecast at least $9.5 million of revenue (including ≥7 system placements) and Q3 gross margin ≥20%, with Q4 gross margin targeted in the mid‑to‑high‑20% range (product margin high‑single to low‑double digits; service margin ~50%). They also guided FY OpEx of $51–$53 million, $8 million of non‑cash expense (~$3M D&A, $5M stock comp), $1M CapEx, $1M interest income and $2M interest expense, reported ~ $20M cash at quarter‑end, expect to access a $10M debt tranche later this year (another $10M possible mid‑2027), and are targeting >20% average annual revenue growth and a 50%+ gross margin exit by 2028 with positive cash flow by end‑2028.
Rapid Micro Biosystems Financial Statement Overview
Summary
Despite strong multi-year and TTM revenue growth and improving gross margin (now positive), results remain dominated by deep operating/net losses, consistently negative operating and free cash flow, and rising leverage as equity shrinks—keeping liquidity and financing risk elevated.
Income Statement
32NegativeBalance Sheet
44NeutralCash Flow
28Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 35.18M | 33.59M | 28.05M | 22.52M | 17.13M | 23.23M |
| Gross Profit | 3.53M | 7.61M | -109.00K | -5.49M | -8.54M | -7.74M |
| EBITDA | -45.64M | -42.74M | -43.51M | -49.33M | -58.55M | -69.25M |
| Net Income | -51.20M | -47.12M | -46.89M | -52.47M | -60.81M | -73.52M |
Balance Sheet | ||||||
| Total Assets | 58.45M | 74.85M | 98.17M | 143.45M | 190.65M | 241.17M |
| Cash, Cash Equivalents and Short-Term Investments | 19.77M | 38.30M | 50.73M | 92.05M | 108.65M | 193.50M |
| Total Debt | 23.48M | 23.87M | 6.17M | 7.35M | 7.97M | 0 |
| Total Liabilities | 40.70M | 41.65M | 22.82M | 25.46M | 26.48M | 20.19M |
| Stockholders Equity | 17.75M | 33.21M | 75.35M | 117.99M | 164.17M | 220.98M |
Cash Flow | ||||||
| Free Cash Flow | -40.39M | -31.91M | -45.52M | -46.93M | -65.29M | -58.18M |
| Operating Cash Flow | -40.06M | -31.06M | -44.15M | -45.08M | -58.55M | -54.96M |
| Investing Cash Flow | 7.12M | 14.33M | 36.66M | 42.15M | -93.47M | -13.29M |
| Financing Cash Flow | 29.29M | 19.77M | 203.00K | 149.00K | 693.00K | 216.75M |
Rapid Micro Biosystems Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RPID, the sentiment is Neutral. The current price of 0.74 is above the 20-day moving average (MA) of 0.73, below the 50-day MA of 0.90, and below the 200-day MA of 2.02, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 44.93 is Neutral, neither overbought nor oversold. The STOCH value of 62.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RPID.
Rapid Micro Biosystems Risk Analysis
Rapid Micro Biosystems disclosed 69 risk factors in its most recent earnings report. Rapid Micro Biosystems reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksRapid Micro Biosystems Peers Comparison
Overall Rating
SGHT62Neutral
LNSR59Neutral
LUNG59Neutral
RPID50Neutral
LUCD48Neutral
HYPR47Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 62Neutral | $583.02M | -20.15 | -51.66% | ― | 16.23% | 41.47% | |
| 59Neutral | $60.36M | 4.17 | 549.37% | ― | 1.59% | ― | |
| 59Neutral | $119.11M | -2.71 | -98.23% | ― | -3.15% | 28.45% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $36.96M | -0.67 | -254.31% | ― | 20.78% | -9.39% | |
| 48Neutral | $82.58M | -0.95 | -610.65% | ― | 23.60% | 54.50% | |
| 47Neutral | $59.64M | -1.87 | -82.89% | ― | 79.96% | 42.64% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| RPID | Rapid Micro Biosystems, Inc. Class A | 0.74 | -3.62 | -83.12% | |
| LUNG | Pulmonx Corporation | 2.73 | 1.35 | 98.19% | |
| LNSR | Lensar Inc | 4.91 | -5.13 | -51.10% | |
| HYPR | Hyperfine Inc. | 0.56 | -0.51 | -47.57% | |
| SGHT | Sight Sciences, Inc. | 10.49 | 3.56 | 51.37% | |
| LUCD | Lucid Diagnostics Inc. | 0.40 | -0.62 | -60.88% |
Rapid Micro Biosystems Corporate Events
Rapid Micro Biosystems Agrees to Merck Acquisition
PositiveOn November 16, 2026, Rapid Micro Biosystems entered a definitive agreement under which Merck KGaA, Darmstadt, Germany, agreed to acquire all outstanding Rapid shares for $0.75 each in cash. The agreement provided for a tender offer followed by a mer...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 17, 2026
